Novo mesto, 26 July (STA) - The pharmaceutical group Krka increased its sales revenues by 7% in the first half of the year to EUR 565.3m compared to the same period last year. However, its profit dropped 3% to EUR 90.1m year-on-year, Krka said at a press conference on Thursday.
Similar to the group, the core company's revenues were up 7% as well to EUR 521.3m, while its profit was 10% lower at EUR 82.9m, according to unaudited data presented today.
The group's operating profit reached EUR 117.1m between January and June, down 5% compared to the same period last year. The company's operating profit was down as well, by 13% to EUR 102.3m.
The group generated 92% of its revenues abroad, while the share of revenue from foreign markets is even higher for the core company, which saw 94% of revenue generated abroad.
Nonetheless, the drug maker saw revenues increase in some markets, most notably in east Europe, where the sales were up by as much as 25%. This region is also Krka's biggest market - some 30% of its products are sold there.
In the first half of the year, the group spent EUR 58m on investments: EUR 26.4m was invested by the company and EUR 31.6m by its subsidiaries.
The data also shows that the number of Krka employees has increased by 3% since January to a total of 9,203 at the end of June.